Mechanism of action of lenalidomide in hematological malignancies
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 928
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Ramsay, A. G., Johnson, A. J., Lee, A. M., Gorgün, G., Le Dieu, R., Blum, W., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 600
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2008) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 425
Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., Pietronigro, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Muller, G. W., Chen, R., Huang, S.-Y., Corral, L. G., Wong, L. M., Patterson, R. T., Chen, Y., Kaplan, G., & Stirling, D. I. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00250-4 · Cited by 341
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 337
Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 319
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Geitz, H., Handt, S., & Zwingenberger, K. (1996) · Immunopharmacology · doi:10.1016/0162-3109(95)00050-x · Cited by 291
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., et al. (2004) · Blood · doi:10.1182/blood-2003-02-0361 · Cited by 289
Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K., Geyer, S. M., Lust, J. A., Allred, J. B., Witzig, T. E., Rajkumar, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-07-032987 · Cited by 273
Interleukin-6 Inhibits Apoptosis of Malignant Plasma Cells
Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., & Berenson, J. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1076 · Cited by 271
Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L.-H., Lu, L., Tang, Y., Shirley, M. A., Muller, G., Schafer, P., Stirling, D., et al. (2005) · Microvascular Research · doi:10.1016/j.mvr.2005.01.002 · Cited by 268
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246
Verhelle, D., Corral, L. G., Wong, K., Mueller, J. H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P. H., Chen, R., Glezer, E., Ferguson, G. D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2317 · Cited by 234
Pellagatti, A., Jädersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610477104 · Cited by 233
Giagounidis, A. A. N., Germing, U., Haase, S., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H., Aivado, M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 212
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
T-cell costimulation–biology, therapeutic potential, and challenges.
Sharpe, A. H., & Abbas, A. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068087 · Cited by 206
Wei, S., Chen, X., Rocha, K., Epling-Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J., Sokol, L., Lawrence, N., Pireddu, R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811267106 · Cited by 192
Properties of thalidomide and its analogues: Implications for anticancer therapy
Teo, S. K. (2005) · The AAPS Journal · doi:10.1208/aapsj070103 · Cited by 184
Niesvizky, R., Jayabalan, D. S., Christos, P. J., Furst, J. R., Naib, T., Ely, S., Jalbrzikowski, J., Pearse, R. N., Zafar, F., Pekle, K., et al. (2008) · Blood · doi:10.1182/blood-2007-05-090258 · Cited by 184
An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
Ebert, B. L., Galili, N., Tamayo, P., Bosco, J., Mak, R., Pretz, J., Tanguturi, S., Ladd-Acosta, C., Stone, R., Golub, T. R., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050035 · Cited by 166
Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 162
Gene expression profiling of CD34+ cells in patients with the 5q− syndrome
Boultwood, J., Pellagatti, A., Cattan, H., Lawrie, C. H., Giagounidis, A., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S., Fidler, C., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06833.x · Cited by 152
Zhang, L., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J. B., Yi, Q., & Wang, M. (2009) · American Journal of Hematology · doi:10.1002/ajh.21468 · Cited by 147
Baz, R., Walker, E., Karam, M. A., Choueiri, T. K., Jawde, R. M. A., Bruening, K., Reed, J., Faiman, B. M., Ellis, Y., Brand, C., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl313 · Cited by 147
Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome
Epling‐Burnette, P. K., Painter, J. S., Rollison, D. E. M., Ku, E., Vendron, D., Widen, R. H., Boulware, D. C., Zou, J., Bai, F., & List, A. F. (2007) · Leukemia · doi:10.1038/sj.leu.2404590 · Cited by 130
Knop, S., Gerecke, C., Liebisch, P., Topp, M. S., Platzbecker, U., Sezer, O., Vollmuth, C., Falk, K., Glasmacher, A., Maeder, U., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184135 · Cited by 120
Shedding light on an old mystery: Thalidomide suppresses survival pathways to induce limb defects
Knobloch, J., & Rüther, U. (2008) · Cell Cycle · doi:10.4161/cc.7.9.5793 · Cited by 101
Gandhi, A. K., Kang, J., Naziruddin, S., Parton, A., Schafer, P. H., & Stirling, D. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.01.010 · Cited by 95
Mitsiades, C. S., Mitsiades, N. S., Richardson, P. G., Munshi, N. C., & Anderson, K. C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21213 · Cited by 87
Immunomodulating drugs for chronic lymphocytic leukaemia
Chanan-Khan, A. A., & Porter, C. W. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70723-9 · Cited by 73
A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T., Figg, W. D., & Royce, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1546 · Cited by 66
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Choueiri, T. K., Dreicer, R., Rini, B. I., Elson, P., Garcia, J. A., Thakkar, S. G., Baz, R. C., Mekhail, T. M., Jinks, H. A., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22290 · Cited by 54
Shannon, E., MIRANDA, R. O., Morales, M. J., & Hastings, R. C. (1981) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1981.tb00169.x · Cited by 54
Sharma, R. A., Steward, W. P., Daines, C. A., Knight, R., O'Byrne, K. J., & Dalgleish, A. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.018 · Cited by 52
Thalidomide: A novel template for anticancer drugs
Stirling, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90032-6 · Cited by 50
Thalidomide--effect on T cell subsets as a possible mechanism of action.
Moncada, B., Ml, B., González‐Amaro, R., Urbina, R., & Ce, L. (1985) · PubMed · Cited by 45
Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes
List, A. F., Baker, A. F., Green, S., & Bellamy, W. T. (2006) · Cancer Control · doi:10.1177/107327480601304s02 · Cited by 43
NEDD1: Function in microtubule nucleation, spindle assembly and beyond
Manning, J. A., & Kumar, S. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.08.012 · Cited by 33
Lenalidomide Therapy for Metastatic Renal Cell Carcinoma
Amato, R. J., Hernandez-McClain, J., Saxena, S., & Khan, M. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31815e451f · Cited by 32
Recent advances in myelodysplastic syndromes
Shadduck, R. K., Latsko, J. M., Rossetti, J. M., Haq, B., & Abdulhaq, H. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.01.022 · Cited by 31
Phase I Study of Lenalidomide in Solid Tumors
Miller, A. A., Case, D., Harmon, M. A., Savage, P. D., Lesser, G. J., Hurd, D. D., & Melin, S. A. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268679.33238.67 · Cited by 22
Kalmadi, S. R., Davis, M., Dowlati, A., O’Keefe, S. J., Cline-Burkhardt, M., Pelley, R. J., Borden, E. C., Dreicer, R., Bukowski, R. M., & Mekhail, T. M. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9025-4 · Cited by 18
Lenalidomide: A New Agent for Patients With Relapsed or Refractory Multiple Myeloma
Tariman, J. D. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.569-574 · Cited by 16
Rodriguez, A. L., Tariman, J. D., Enecio, T., & Estrella, S. M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.579-589 · Cited by 16
Zhang, M. M., Chan, J. K., Husain, A., Guo, H. H., & Teng, N. N. H. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.11.026 · Cited by 15
Cited by
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 486
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
Metadata
- Authors
- Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A.
- Venue
- Journal of Hematology & Oncology
- Published
- 2009-08-12
- Volume
- 2
- Issue
- 1
- Pages
- 36-36
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W1980068016
- Cited by
- 467
- References
- 68
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.